Rate My Professor Archana Sud

Professor Sud's research centers on infectious diseases, with particular emphasis on methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, antibiotic therapy optimization, and clinical trial design. She played a key role in the CAMERA2 randomized clinical trial, which assessed the efficacy of adding anti-staphylococcal β-lactams to vancomycin or daptomycin. Her seminal publication, 'Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial' (2020), has garnered substantial citations. Subsequent post-hoc analyses from CAMERA2 include 'Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial' (2023), 'Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia' (2025), and explorations of hierarchical composite endpoints and desirability of outcome rankings (2024-2026). Additional contributions encompass the Staphylococcus aureus Network Adaptive Platform (SNAP) trial protocol for early oral antibiotic switches (2023), periprosthetic joint infection management (2020, 2022), and telehealth applications for chronic disease patients during the COVID-19 pandemic (2020). With 74 publications and over 3,172 citations, her work has advanced evidence-based practices in infectious disease management. She serves as Principal Investigator in multicenter trials, such as the Randomised Arthroplasty Infection Network study.